Stocks-SOBI.ST-Swedish Orphan Biovitrum AB

SOBI.ST Swedish Orphan Biovitrum AB

309.50 1.10 (0.36%)
Market ClosedIn SEK
Trade
Stocks-SOBI.ST-Swedish Orphan Biovitrum AB
SOBI.ST Swedish Orphan Biovitrum AB
Trade

Swedish Orphan Biovitrum AB price

-3.07% Past Week
Created with Highcharts 4.2.7 /Highstock 4.2.7
Market Cap
105.43B
Day’s Range
305.34
-
312.53
52W Range
205.29
-
321.91
Volume (3M)
335.58K
Price-Earnings Ratio
48.62
Revenue
23.71B
Top Discussions
NordicEconomy
United Kingdom
3 days ago
Dear Investors, Here is your monthly update for August 2024 ✨ August 2024 started with extreme volatility in global markets, with fears of a hard landing in the US economy and the expectancy of bigger rate cuts. During the month, markets recovered most of the losses, leading to a powerfull rally in... Show More
Like CommentShare
null
.
TayfurSener
Australia
about a month ago
$CERS (Cerus Corp) $GRFS (Grifols SA) $SOBI.ST (Swedish Orphan Biovitrum AB) $TDOC (Teladoc Health Inc) $EHTH (eHealth Inc) With news of pretty much all the big pharma companies who dished out the jabs now acquiring companies that develop medicines and technologies relating to heart disease and... Show More
Like CommentShare
null
.
MarketUpdates
United Kingdom
7 months ago
$SOBI.ST (Swedish Orphan Biovitrum AB) Q1 2024 earnings report is expected to be released
25
APR
Reports
Q1, 2024 earnings report expected
SOBI.ST
SOBI.ST
Swedish Orphan Biovitrum AB
309.50
1.10
(0.36%)
Trade
Like CommentShare
MarketUpdates
United Kingdom
7 months ago
$SOBI.ST (Swedish Orphan Biovitrum AB) Q1 2024 earnings report is expected to be released
25
APR
Reports
Q1, 2024 earnings report expected
SOBI.ST
SOBI.ST
Swedish Orphan Biovitrum AB
309.50
1.10
(0.36%)
Trade
Like CommentShare
MarketUpdates
United Kingdom
10 months ago
$SOBI.ST (Swedish Orphan Biovitrum AB) Q4 2023 earnings report is expected to be released
8
FEB
Reports
Q4, 2023 earnings report expected
SOBI.ST
SOBI.ST
Swedish Orphan Biovitrum AB
309.50
1.10
(0.36%)
Trade
Like CommentShare
MarketUpdates
United Kingdom
10 months ago
$SOBI.ST (Swedish Orphan Biovitrum AB) Q4 2023 earnings report is expected to be released
8
FEB
Reports
Q4, 2023 earnings report expected
SOBI.ST
SOBI.ST
Swedish Orphan Biovitrum AB
309.50
1.10
(0.36%)
Trade
Like CommentShare
Amicosssss
Italy
12 months ago
🇺🇸 NORWAY: rates +25bp to +4.25% SWEDEN: rates +25bp to +4% SWITZERLAND: rates unchanged at 1.75% (inflation at +1.6% below the 2% target) 🇮🇹 NORVEGIA: tassi +25pb al +4,25% SVEZIA: tassi +25pb al +4% SVIZZERA: tassi invariati all’1,75% (inflazione al +1,6% al di sotto del target del 2%) $NAS.OL... Show More
Like CommentShare
MarketUpdates
United Kingdom
about a year ago
Edited
$SOBI.ST (Swedish Orphan Biovitrum AB) Q3 2023 earnings report is expected to be released
30
OCT
Reports
Q3, 2023 earnings report expected
SOBI.ST
SOBI.ST
Swedish Orphan Biovitrum AB
309.50
1.10
(0.36%)
Trade
Like CommentShare
MarketUpdates
United Kingdom
about a year ago
Edited
$SOBI.ST (Swedish Orphan Biovitrum AB) Q3 2023 earnings report is expected to be released
undefined logo
SOBI.ST
Swedish Orphan Biovitrum AB
308.93
1.10 (0.36%)
Trade
Like CommentShare
MarketUpdates
United Kingdom
about a year ago
Edited
$SOBI.ST (Swedish Orphan Biovitrum AB) Q3 2023 earnings report is expected to be released
undefined logo
SOBI.ST
Swedish Orphan Biovitrum AB
308.93
1.10 (0.36%)
Trade
Like CommentShare

About Swedish Orphan Biovitrum AB

Sobi is a global biopharmaceutical company based in Stockholm, Sweden. Sobi is focused on medical solutions for rare diseases and is active in two therapeutic areas – Hematology and Immunology, in addition, the company has a portfolio of Specialty Care products. The company’s activity spans 25 countries, delivering treatments to patients in over 70 countries across the globe. Sobi employs approximately1,300 people across Europe, the Middle East, North Africa, North America, and Russia. Sobi’s in-house capabilities include late stage R&D, biologics manufacturing and supply, patient access and distribution, and more. The company’s immunology portfolio includes three products and is considered a leading company in treating hemophilia and providing community support in hemophilia care. In 2019, the company announced the acquisition of Dova Pharmaceuticals through a merger. Sobi’s share is listed on Nasdaq Stockholm. The company’s financial results for the third quarter of fiscal 2019 included reported growth in revenue of 27%, reaching SEK 2,930 million. Invest in this instrument and stay updated on recent SOBI.ST value changes.
Guido Oelkers, PhD
CEO
1.7K
Employees
2001
Founded
SE
HQ
Show More
Med TechStockholm

ESG: A New Source of Insight

What is an ESG Score?
This number is a measure of a company’s exposure to environmental, social, and governance risks. Influencing factors include energy efficiency, safety, social policies, and more. Learn More
Powered by ESG Book
Get insight into a company's sustainability using ESG (environmental, social, and governance) scores.
0
100
61
Very High
Industry 
Avg. 46 
73
Environment
57
Social
64
Governance

People Also Bought